Related content

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers

By LLerena Adrian   Dorado Pedro   Ramírez Ronald   Calzadilla Luis R   Peñas-LLedó Eva   Álvarez Mayra   Naranjo María EG   González Idilio   Pérez Bárbaro  

Pharmacogenomics, Vol. 14, Iss. 16, 2013-12 ,pp. : 1973-1977

Future Medicine

Access to resources Recommend Favorite

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta   Nordmark Anna   Pihlsgård Maria   Mahindi Margarita   Bertilsson Leif   Gustafsson Lars  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

By Sehrt Daniel   Meineke Ingolf   Tzvetkov Mladen   Güültepe Senol   Brockmööller Jüürgen  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 783-795

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism

By  

Current Pharmaceutical Design, Vol. 13, Iss. 2, 2007-01 ,pp. : 241-250

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?

By Higgins Michaela J.   Rae James M.   Flockhart David A.   Hayes Daniel F.   Stearns Vered  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 2, 2009-02 ,pp. : 203-213

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite